Dr. Samuel Z. Goldhaber
Harvard Medical School, Massachusetts, USA
Dr. Samuel Z. Goldhaber, Professor of Medicine at Harvard Medical School, is Section Head of Vascular Medicine in the Cardiovascular Medicine Division at Brigham and Women’s Hospital (BWH). He is Director of the BWH Thrombosis Research Group and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism, stroke prevention in atrial fibrillation, and novel oral anticoagulants.
Dr. Goldhaber showed through a series of clinical trials that right ventricular dilatation and hypokinesis predict an adverse prognosis in acute pulmonary embolism. Furthermore, these trials showed that systemic and catheter-based ultrasound-facilitated thrombolytic therapy, more rapidly than heparin, restored normal right ventricular function. He also conducted a randomized trial demonstrating that electronic medical alerts for high risk hospitalized patients not receiving venous thromboembolism prophylaxis reduce the symptomatic DVT and pulmonary embolism rates by more than 40%.
Dr. Goldhaber serves as Chair of the Steering Committee of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored ATTRACT Trial of DVT, which has tested pharmacomechanical low-dose thrombolysis against standard anticoagulation to prevent postthrombotic syndrome. He serves on the Steering Committees of the GARFIELD Atrial Fibrillation and GARFIELD-Venous Thromboembolism cohort studies and is the National Coordinator of participating USA sites in GARFIELD-AF and in GARFIELD-VTE. Dr. Goldhaber is BWH Site Principal Investigator for the ongoing NHLBI-sponsored Cardiovascular Inflammation Reduction Trial. For his work on prevention of venous thromboembolism, Dr. Goldhaber received the Certificate of Appreciation from the Surgeon General of the United States. In 2015, he received the Distinguished Scientist Award from the American Heart Association.
Dr. Goldhaber directs a series of Harvard Medical School courses, including a 5-day update in clinical cardiology and a 2-day course on thrombosis and thromboembolism. Dr. Goldhaber is President and Founding Director of the nonprofit organization, North American Thrombosis Forum (www.NATFonline.org), which focuses on thrombosis education for healthcare providers, patients, and the public. At Brigham and Women’s Hospital, he runs a busy outpatient practice of general cardiology, venous thromboembolism, and atrial fibrillation patients, and oversees the inpatient Cardiology Consult Service.